New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
12:19 EDTLVLT, SNDK, COV, DWA, TWTC, MDT, BLUE, YHOO, FIOOn The Fly: Midday Wrap
Stocks on Wall Street have traded on both sides of the ledger this morning, as investor concerns over the developing situation in Iraq are competing with another flurry of merger activity. There were a number of economic reports released during the morning, though the data had little effect on the market. Near noon the major averages were slightly lower, but once again moving in a narrow range, as headlines about the advance of insurgents in Iraq continue to dominate the news flow. ECONOMIC EVENTS: In the U.S., industrial production increased 0.6% in May, versus an expected increase of 0.5%, while capacity utilization rose slightly to 79.1%. The NY Fed Empire state survey for June ticked up to a four-year high of 19.3, which was higher than expected. The NAHB homebuilder survey index climbed to 49 in June, beating expectations for it to rise from its previous reading of 45 to 47. COMPANY NEWS: A number of merger and acquisition deals were announced over the weekend and this morning, headlined by a another pharmaceutical industry mega-merger. Medtronic (MDT) agreed to acquire Ireland's Covidien (COV) in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9B based on Medtronic's closing stock price on June 13. Following the deal announcement, Covidien shares trading in New York rose 19%. Medtronic, which also raised its dividend by 9% this morning, was upgraded at both William Blair and JPMorgan, though it declined about 2.5% near noon. Meanwhile, SanDisk (SNDK) agreed to acquire Fusion-io for $11.25 per share in cash, or $1.1B net of cash assumed. SanDisk rose 3% following the deal, which Piper Jaffray said expands the company's enterprise and hyper-scale product line-up. Research firm Craig-Hallum said in a note to investors that it believes another interested party could step-in and make a bid for Fusion-io, which was up about 23% to $11.39 in midday trading, or 14c above the price agreed to by SanDisk. Additionally, Level 3 (LVLT) agreed to acquire tw telecom (TWTC) for $10 cash and 0.7 shares of Level 3 common stock per share in a transaction valued at $40.86 per share based on market close as of June 13. MAJOR MOVERS: Among the notable gainers outside of the M&A newsmakers was Bluebird bio (BLUE), which jumped 35% after reporting data over the weekend that Piper Jaffray believes solidifies LentiGlobin prospects in one indication and positions it attractively for another indication that is also being pursued for the drug. Among the noteworthy losers was family-film producer DreamWorks Animation (DWA), which dropped 11.5% after its latest film, "How to Train Your Dragon 2," didn't do as well as analysts had expected in its box-office debut. Also lower were shares of Yahoo! (YHOO), which fell 5% after Alibaba disclosed additional information about its revenue, income and other financial data as its gets closer to its planned initial public offering. Yahoo continues to be a significant shareholder in the Chinese e-commerce company, whose coming stock offering could surpass Facebook’s (FB) record as the biggest tech IPO. INDEXES: Near midday, the Dow was down 23.37, or 0.14%, to 16,752.37, the S&P 500 was down 1.00, or 0.05%, to 1,935.16, and the Nasdaq was virtually flat at 4,310.44.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 25, 2015
10:08 EDTYHOOYahoo higher after canceling appearance at tech conference
Yahoo has canceled its appearance at next week's technology conference hosted by Credit Suisse, according to sources. The reason behind the cancelation remains unclear. Shares of Yahoo are up 45c to $33.41 in early trading.
09:58 EDTYHOOYahoo November weekly options active
Yahoo November 33 and 34 calls are active on total call volume of 3,700 contracts (puts 1300 contracts). November weekly call option implied volatility is at 26, December is at 34, January is at 33; compared to its 52-week range of 14 to 33. Active options volume suggests traders taking positions for price movement.
November 24, 2015
08:31 EDTMDTMedtronic remains a top tier performer in Med Device space, says Cowen
Subscribe for More Information
06:16 EDTYHOOInsiders losing patience with Yahoo CEO Mayer's growth plan, WSJ says
Subscribe for More Information
November 22, 2015
19:37 EDTYHOOTop Yahoo media executive leaves company, Re/code says
Subscribe for More Information
November 20, 2015
11:45 EDTSNDKNimble Storage plummets to 52-week low after results, guidance trail estimates
Shares of Nimble Storage (NMBL), a flash storage solutions provider, are plunging after the company's third quarter results and fourth quarter outlook significantly trailed analysts' consensus estimates. WHAT'S NEW: Thursday night after the close, Nimble Storage reported Q3 adjusted earnings per share of (14c) and revenue of $80.7M, well below the consensus of (8c) and $87.44M, respectively. Q3 non-GAAP gross margin was 66.9% compared to 67.1% in the prior year period. GUIDANCE: Looking ahead to Q4, Nimble Storage forecast adjusted EPS of (13c)-(11c) and revenue of $87M-$90M, far below the estimates of 0c and $99.2M respectively. EXECUTIVE COMMENTARY: Suresh Vasudevan, Chief Executive Officer of Nimble Storage, noted that the company's enterprise investments were "taking longer to become fully productive" and that the shift in investment from commercial to enterprise business "impacted its commercial revenue growth more than they anticipated." Chief Financial Officer Anup Singh said, "We plan to make some key investments to drive growth that will constrain short-term profitability. We believe our planned investments will improve revenue growth as well as operating leverage over time. We expect that it will take several quarters to realize the impact of these investments and have factored that into our guidance for Q4 FY16." ANALYST REACTION: Friday morning there was a wealth of analyst commentary, with eleven separate firms downgrading Nimble Storage. Conversely, Piper Jaffray analyst Andrew Nowinski said Nimble Storage was oversold following the company's Q3 miss and push out of its break-even point beyond 2016. Estimates and the stock's valuation have been de-risked, Nowinski told investors in a post-earnings research note. He kept an Overweight rating on the name and lowered his price target for Nimble to $20 from $37. Jefferies analyst James Kisner recommended using the significant pullback in shares of Nimble Storage as a buying opportunity. Despite the missed Q3 revenue and disappointing Q4 guidance, Nimble's hybrid storage technology remains well differentiated and the total addressable market is large, Kisner told investors in a post-earnings research note. He cut his price target for shares to $20 from $33 and kept a Buy rating on the name. After Nimble reported weaker than expected results, Sterne Agee CRT still believes that the company has "a healthy franchise" in the $75,000-$125,000 price range. The firm continues to believe that the company's Hybrid product is differentiated from competing systems. It kept a Buy rating on the shares. PRICE ACTION: In late morning trading, Nimble Storage fell $10.37, or over 50%, to $10.02 on more than seven times its average daily trading volume. As the session unfolds, the stock continues to hit fresh 52-week lows. Over the past 12 months, the stock is down approximately 62%. OTHERS TO WATCH: Other flash storage solutions providers include Pure Storage (PSTG), down 13%, NetApp (NTAP), up fractionally, SanDisk (SNDK), down fractionally, and Violin Memory (VMEM) down over 6%.
05:22 EDTMDTStocks with implied volatility movement; MDT UNH
Stocks with implied volatility movement; Medtronic (MDT) 25, UnitedHealth (UNH) 30 according to iVolatility.
November 19, 2015
10:25 EDTBLUEPiper Jaffray healthcare analyst holds an analyst/industry conference call
Sr Research Analyst Schimmer, along with Dr. Alan Cohen, member of the Medical Advisory Board of the Cooley's Anemia Foundation, discuss the emerging treatment options for Beta Thalassemia and Sickle Cell and emerging clinical data for key programs including Bluebird and Bellicum Pharmaceuticals on an Analyst/Industry conference call to be held on November 20 at 1 pm.
08:03 EDTYHOOStarboard urges Yahoo to sell core businesses
In a letter delivered to Yahoo's Chairman, CEO And board, Starboard stresses that a proposed spin-off of Aabaco Holdings is not Yahoo's best alternative. It adds that a sales of Yahoo's core business would be the best risk-adjusted outcome for shareholders. In the letter, Starboard stated, "We have grown increasingly frustrated with your unwillingness to accept our help and your dismissive approach to our serious concerns about the current situation at Yahoo! Inc. ("Yahoo"). As you, the management team, and your advisors requested from us over a year ago, we have attempted to work with you privately and agreed not to pursue the nomination and election of directors at last year's annual meeting. Despite our numerous conversations and meetings, and notwithstanding your willingness to provide us an audience, you have been reluctant to respond or adapt to the realities of the current environment. The current situation that Yahoo faces is so important that we now feel it is necessary to communicate with management and the Board of Directors in a manner such that our message is not only as explicit as possible for you, but also for our fellow Yahoo shareholders. The proposed spin-off of Aabaco Holdings is not Yahoo's best alternative. Instead, you should be exploring a sale of Yahoo's core Search and Display advertising businesses and leave Yahoo's ownership stakes in Alibaba Group and Yahoo Japan in the existing corporate entity."
06:00 EDTYHOOStarboard sends letter to Yahoo, urges halt of Alibaba spinoff plan, WSJ reports
Yahoo (YHOO) shareholder Starboard Value sent a letter to the company urging the company to halt the plan to sell its stake in Alibaba (BABA) due to the risk of incurring taxes on the sale, the Wall Street Journal reports. The activist investor instead wants Yahoo to sell its struggling Internet business, the report says. Starboard supported the sale of over $20B in Alibaba shares before the IRS denied Yahoo's request for a private letter ruling on whether the spinoff would be considered tax free. Reference Link
November 18, 2015
10:29 EDTSNDKOptions with increasing implied volatility
Options with increasing implied volatility: TERP CSC SGMS RH BBRY ULTA SNDK ORCL NKE VNET
10:02 EDTBLUEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Align Technology (ALGN) initiated with an Overweight at Piper Jaffray... Allegion (ALLE) initiated with a Buy at BofA/Merrill... Atara Biotherapeutics (ATRA) assumed with a Neutral at Goldman... Bankrate (RATE) initiated with a Buy at Topeka... Boulder Brands (BDBD) initiated with a Buy at Wunderlich... (CRCM) initiated with a Hold at Topeka... Coeur Mining (CDE) initiated with a Hold at Noble Financial... E.W. Scripps (SSP) initiated with an Equal Weight at Stephens... Etsy (ETSY) initiated with a Hold at Topeka... Euronet (EEFT) initiated with a Hold at Feltl... Fulton Financial (FULT) initiated with a Neutral at JPMorgan... Gray Television (GTN) initiated with an Overweight at Stephens... HP Enterprise (HPE) initiated with a Market Perform at Raymond James... Halozyme (HALO) initiated with a Buy at Citi... Incyte (INCY) initiated with a Buy at Goldman... Inventure Foods (SNAK) initiated with a Buy at Wunderlich... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Goldman... Kite Pharma (KITE) initiated with a Buy at Goldman... Landec (LNDC) initiated with a Buy at Wunderlich... Lendingtree (TREE) initiated with a Buy at Topeka... Media General (MEG) initiated with an Equal Weight at Stephens... Meredith (MDP) initiated with an Equal Weight at Stephens... Nexstar (NXST) initiated with an Overweight at Stephens... OSI Systems (OSIS) initiated with a Buy at BB&T... PriceSmart (PSMT) initiated with an Outperform at Scotia Howard Weil... Qorvo (QRVO) initiated with an Outperform at JMP Securities... Seattle Genetics (SGEN) initiated with a Sell at Goldman... Sinclair Broadcast (SBGI) initiated with an Equal Weight at Stephens... TEGNA (TGNA) initiated with an Overweight at Stephens... Tribune Media (TRCO) initiated with an Equal Weight at Stephens... Xenia Hotels & Resorts (XHR) initiated with an Outperform at JMP Securities... bluebird bio (BLUE) initiated with a Buy at Goldman.
08:40 EDTBLUEbluebird bio December volatility up into clinical updates
Subscribe for More Information
08:32 EDTBLUEGoldman sees bluebird shares doubling on 'one-shot' gene therapy
Following a three and a half year rally for biotech stocks, and a more recent sector pullback from July's record high levels, Goldman Sachs analyst Salveen Richter said in a new note to investors that he has a Neutral view of the small- to mid-cap biotech space. Richter believes select small- to mid-cap biotech stocks should continue to outperform the broader market, but thinks stock picking is essential and laid out for investors who he thinks the winning and losing stocks in the space are likely to be. BUY BLUEBIRD: bluebird bio's (BLUE) innovative platform, which is designed to cure genetic diseases by introducing functional gene copies into a patient, makes it the "leading gene therapy play," contends Richter. bluebird's key value driver is LentiGlobin, a gene therapy for rare blood disorders, beta-thalassemia major and sickle cell disease, the analyst points out. Richter, who notes that bluebird has a major upcoming catalyst in the form of clinical updates from three Phase I/II studies of LentiGlobin in beta-thalassemia and sickle cell disease, set a 12-month price target of $165 on the stock, giving it 107% upside from current levels if his target is achieved. OTHERS TO BUY: Richter also recommends that investors own leading names in three areas of innovation, namely orphan diseases, gene therapy/editing, and immuno-oncology. In those areas, he identifies BioMarin (BMRN) as an orphan drug stock to buy, Incyte (INCY) as the best-positioned biotech immuno-oncology play for 2016 and Kite Pharma as a stock to own for the company's engineered T-cell platform focused on cancer. He set Buy rating on each of the three aforementioned names. SELL SEATTLE GENETICS: The only stock in the small- to mid-cap biotech space that Richter initiated coverage of with a Sell rating is Seattle Genetics (SGEN). The analyst acknowledges that the company is currently a leader in the antibody drug conjugate field, but thinks the consensus view of future competition for its Adcetris drug is "optimistic" and that the outlook for the rest of its pipeline is unclear. Richter set a 12-month price target of $33 on the stock, giving it 27% downside from current levels if his target is achieved. The analyst also began coverage of Atara Biotherapeutics (ATRA), Isis Pharmaceuticals (ISIS) and Juno Therapeutics (JUNO) with Neutral ratings, as he sees them all as having interesting drug platforms, but also believes their prospects are appropriately reflected in current valuations of their stocks. PRICE ACTION: Over the last six month, bluebird bio shares have fallen nearly 50%, but the stock has still more than doubled from where it was one year ago. In the last six months Seattle Genetics has risen 13%, bringing its gains over a one year timeframe to 28%.
08:19 EDTSNDKRBC Capital to hold a tour
Subscribe for More Information
07:28 EDTYHOOYahoo taxes could amount to more than value of Alibaba stake, says SunTrust
Subscribe for More Information
06:24 EDTBLUEbluebird bio initiated with a Buy at Goldman
Subscribe for More Information
06:15 EDTYHOOYahoo included in New York's daily fantasy sports investigation, Reuters says
An investigation by the New York attorney general into the daily fantasy sports industry will no include Yahoo, Reuters reports, citing a person familiar with the matter. Yahoo operates its own daily fantasy site and received a subpoena by New York AG Eric Schneiderman, the report says. Reference Link
November 17, 2015
09:14 EDTMDTMedtronic announces FDA approval, launch of MyCareLink Smart Monitor
Subscribe for More Information
08:50 EDTYHOOCheetah Mobile reports strategic partnership with Yahoo
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use